Studies like this upend the notion that #CTOPCI ‘does very little (or nothing)’ physiologically for a well collateralized CTO. 

One could argue that there is more robust physiologic data for improved perfusion when the appropriate tools are used (FFR, PET etc).

Whether this improvement translates into clinical benefit is a more nuanced question - no for mortality and yes for QOL. 

My take - #CTOPCI only works if there is a) viable tissue beyond the CTO, and b) there is an identifiable QOL issue (which includes DOE). 

How do you decide when to treat a CTO and when yo walk away from it?
#ctopci
#CTOPCI